These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. [Complete androgen blockage in the treatment of metastatic prostate cancer]. Matzkin H; Braf Z Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104 [No Abstract] [Full Text] [Related]
36. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801 [TBL] [Abstract][Full Text] [Related]
37. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate]. Culine S Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025 [No Abstract] [Full Text] [Related]
38. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366 [TBL] [Abstract][Full Text] [Related]
39. [New perspectives in the drug therapy of hormone-resistant prostate cancer]. Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko VM Vopr Onkol; 2010; 56(6):645-53. PubMed ID: 21395118 [No Abstract] [Full Text] [Related]
40. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]